Prof. MUDr. Jaroslav Blahoš, DrSc. - an 80-year-old youngsterPersonalia

V. Palička

Clin Osteol 2010; 15(2): 47

The role of parathormone, calcitonin and sclerostin in the regulation of bone remodellingReview articles

V. Zikán

Clin Osteol 2010; 15(2): 48-50

Bone is continuously remodelled to maintain its strength and mineral homeostasis. Osteocytes play an essential role in bone remo­ delling. The discovery of sclerostin, an osteocyte-derived inhibitor of Wnt signalling and bone formation, has provided new insights into communication networks between bone cells. In this review, we look at what is known about calciotropic hormones, parathyroid hormone and calcitonin, and osteocyte-derived sclerostin in the regulation of bone remodelling.

Osteoporosis in spondylarthritidesReview articles

K. Pavelka

Clin Osteol 2010; 15(2): 51-56

Spondyloarthritis is a group of inflammatory rheumatic diseases involving the spine, peripheral joints and periarticular soft tissues, having frequent extraskeletal manifestations. Ankylosing spondylitis (AS) is the most frequent entity, with the highest prevalence of osteoporosis (OP). The prevalence of OP in AS cohort studies is 19-62 %. Bone mineral density (BMD) assessment is methodically difficult in the lumbosacral spine where the presence of syndesmophytes interferes with measurement. Therefore, it is more conveni­ ent to measure BMD in the femoral neck or to use QCT of the lumbar spine. Decreases BMD correlates with disease duration, AS ac­...

Risk of osteoporotic fractures in diabetic patients treated with glitazonesReview articles

J. Payer, P. Jackuliak, Z. Killinger

Clin Osteol 2010; 15(2): 57-60

Osteoporosis is a common complication in patients with both types of diabetes mellitus. In type 2 diabetes patients, the important risk factors for osteoporotic fractures include the use of glitazones. As selective agonists of a group of nuclear receptors, the so-called pe­ roxisome proliferator-activated receptor gamma (PPAR-y), glitazones participate in the inhibition of osteoblast differentiation and sti­ mulation of osteoclasts from haematopoietic cells. The effect is clinically manifested by a higher rate of osteoporotic fractures at pre­ dilection sites (the distal lower extremities and upper extremities), especially in the population at risk,...

Nutrition in secondary osteoporosis due to gastrointestinal diseaseReview articles

P. Fojtík, P. Novosad, O. Urban

Clin Osteol 2010; 15(2): 62-67

Secondary osteoporosis is more frequent than expected, with the prevalence of 30-60 % in men and 50 % in perimenopausal women. The most frequent postmenopausal osteoporosis might be combined with secondary osteoporosis and diagnosing and treating these patients might be challenging. The main cause of secondary osteoporosis are gastrointestinal diseases such as inflammatory bowel di­ seases (Crohn's disease, ulcerative colitis), coeliac disease, chronic cholestatic liver disease, gastric and intestinal surgery, pancreatic exocrine insufficiency, lactose intolerance and glucocorticosteroid treatment. Patients with osteoporosis are usually treated by...

Pleiotropic role of vitamin D and its active metabolites in the treatment of osteoporosisReview articles

P. Horák, M. Skácelová, M. Žurek, J. Zadražil

Clin Osteol 2010; 15(2): 68-74

Assessment of the efficacy of osteoporosis treatmentInformations

J. Štěpán

Clin Osteol 2010; 15(2): 75-79

News from around the worldLiterature

Clin Osteol 2010; 15(2): 80-83